Titanium
(Ti) and titanium alloys have been widely used in the
field of biomedicine. However, the unmatched biomechanics and poor
bioactivities of conventional Ti implants usually lead to insufficient
osseointegration. To tackle these challenges, it is critical to develop
a novel Ti implant that meets the bioadaptive requirements for load-bearing
critical bone defects. Notably, three-dimensional (3D)-printed Ti
implants mimic the microstructure and mechanical properties of natural
bones. Additionally, eco-friendly techniques based on inorganic-binding
peptides have been applied to modify Ti surfaces. Herein, in our study,
Ti surfaces were modified to reinforce osseointegration using chimeric
peptides constructed by connecting W9, RP1P, and minTBP-1 directly
or via (GP)4, respectively. PR1P is derived
from the extracellular VEGF-binding domain of prominin-1, which increases
the expression of VEGF and promotes the binding of VEGF to endothelial
cells, thereby accelerating angiogenesis. W9 induces osteoblast differentiation
in bone marrow mesenchymal stem cells and human mesenchymal stem cells
to promote bone formation. Overall, chimeric peptides promote osseointegration
by promoting angiogenesis and osteogenesis. Additionally, chimeric
peptides with P3&4 were more effective than those with P1&2
in improving osseointegration, which might be ascribed to the capacity
of P3&4 to provide a greater range for chimeric peptides to express
their activity. This work successfully used chimeric peptides to modify
3D-Ti implant surfaces to improve osseointegration on the implant–bone
surface.